RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESS WIRE)--Sept. 21, 2006--Tranzyme Pharma announced today that the Company has amended the IND for its novel small molecule ghrelin agonist, TZP-101, to include patients with gastroparesis. Tranzyme has been developing TZP-101 as a potent prokinetic agent for the treatment of post-operative ileus (POI). Under the amended IND, Tranzyme has initiated a single-dose study in diabetic patients suffering from gastroparesis. This new study will provide a lead-in to more detailed Phase II evaluation of TZP-101 in both POI and gastroparesis.
